(Total Views: 550)
Posted On: 08/26/2020 9:53:04 AM
Post# of 72446
Re: someconcerns #66174
Great news!
WAKEFIELD, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals ( IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that Dr. William F. DeGrado has joined the Company as a Scientific Advisor. In this role, he will help guide the continuing clinical development of Brilacidin, the Company’s defensin-mimetic drug candidate, including against SARS-CoV-2 (COVID-19).
“I am excited to be involved again with Brilacidin, a unique biomimetic drug candidate that has been properly advanced clinically by Innovation across multiple indications,” said William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF). “I look forward to collaborating with the Innovation team—most urgently, toward developing Brilacidin as a promising therapeutic to treat the novel coronavirus and possibly other viruses. Brilacidin already has exhibited intriguing anti-SARS-CoV-2 in vitro inhibitory efficacy at clinically-achievable concentrations based on Brilacidin pharmacokinetics seen in earlier clinical testing. The world is in dire need of new antiviral treatments and Brilacidin is well-positioned potentially to emerge as one.”
Read More: https://investorshangout.com/post/view?id=587...z6WETR1Bhi
WAKEFIELD, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals ( IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that Dr. William F. DeGrado has joined the Company as a Scientific Advisor. In this role, he will help guide the continuing clinical development of Brilacidin, the Company’s defensin-mimetic drug candidate, including against SARS-CoV-2 (COVID-19).
“I am excited to be involved again with Brilacidin, a unique biomimetic drug candidate that has been properly advanced clinically by Innovation across multiple indications,” said William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF). “I look forward to collaborating with the Innovation team—most urgently, toward developing Brilacidin as a promising therapeutic to treat the novel coronavirus and possibly other viruses. Brilacidin already has exhibited intriguing anti-SARS-CoV-2 in vitro inhibitory efficacy at clinically-achievable concentrations based on Brilacidin pharmacokinetics seen in earlier clinical testing. The world is in dire need of new antiviral treatments and Brilacidin is well-positioned potentially to emerge as one.”
Read More: https://investorshangout.com/post/view?id=587...z6WETR1Bhi
(7)
(0)
